Endothelial activation and development of coronary artery disease in transplanted human hearts

JAMA

Volumn 278, Issue 14, 1997, Pages 1169-1175

  Labarrere, Carlos A ^a   Nelson, David R ^b   Faulk, W Page ^a  

^a METHODIST RESEARCH INSTITUTE   (United States)

^b INDIANA UNIVERSITY HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA DR ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1;

ADULT; ARTERY ENDOTHELIUM; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; GRAFT FAILURE; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HUMAN; IMMUNOCYTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR;

EID: 0030874151     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.278.14.1169     Document Type: Article

References (45)

1. Gao S-Z, Hunt SA, Schroeder JS, Alderman EL, Hill IR, Stinson EB. Early development of accelerated graft coronary artery disease: risk factors and course. J Am Coll Cardiol. 1996;28:673-679.
2. Miller LW, Wolford TL, Donohue TJ, Drury JH. Cardiac allograft vasculopathy: new insights from intravascular ultrasound and coronary flow measurements. Transplant Rev. 1995;9:77-96.
3. Faulk WP, Labarrere CA. Fibrinolytic and anticoagulant control of hemostasis in human cardiac and renal allografts. Major Probl Pathol. 1994;30: 49-65.
4. Johnson DE, Gao S-Z, Schroeder JS, De Campli WM, Billingham ME. The spectrum of coronary artery pathologic findings in human cardiac allografts. J Heart Transplant. 1989;8:349-359.
5. Faulk WP, Labarrere CA. Vascular immunopathology and atheroma development in human allografted organs. Arch Pathol Lab Med. 1992;116: 1337-1344.
6. Schroeder JS, Hunt SA. Chest pain in heart-transplant recipients. N Engl J Med. 1991;324:1805-1807.
7. Topol EJ, Nissen SE. Our preoccupation with coronary luminology: the dissociation between clinical and angiographic findings in ischemic heart disease. Circulation 1995;92:2333-2342.
8. Salomon RN, Hughes CCW, Schoen FJ, Payne DD, Pober JS, Libby P. Human coronary transplantation-associated arteriosclerosis: evidence for a chronic immune reaction to activated graft endothelial cells. Am J Pathol. 1991;138:791-798.
9. Taylor PM, Rose ML, Yacoub MH, Pigott R. Induction of vascular adhesion molecules during rejection of human cardiac allografts. Transplantation. 1992;54:451-457.
10. Tanio JW, Basu CB, Albelda SM, Eisen HJ. Differential expression of the cell adhesion molecules ICAM-1, VCAM-1, and E-selectin in normal and post-transplantation myocardium: cell adhesion molecule expression in human cardiac allografts. Circulation. 1994;89:1760-1768.
11. Labarrere CA, Pitts D, Nelson DR, Faulk WP. Coronary artery disease in cardiac allografts: association with arteriolar endothelial HLA-DR and ICAM-1 antigens. Transplant Proc. 1995;27:1939-1940.
12. Poston RN, Haskard DO, Coucher JR, Gall NP, Johnson-Tidey RR. Expression of intercellular adhesion molecule-1 in atherosclerotic plaques. Am J Pathol. 1992;140:665-673.
13. Labarrere CA, Pitts D, Nelson DR, Faulk WP. Vascular tissue plasminogen activator and the development of coronary artery disease in heart transplant recipients. N Engl J Med. 1995; 333:1111-1116.
14. Billingham ME, Cary NRB, Hammond ME, et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group: The International Society for Heart Transplantation. J Heart Transplant. 1990;9:587-593.
15. Grattan MT, Moreno-Cabral CE, Starnes VA, Oyer PE, Stinson EB, Shumway NE. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA. 1989;261: 3561-3566.
16. Schoen JF. Blood vessels. In: Cotran RS, Kumar V, Robbins SL, eds. Robbins Pathologic Basis of Disease. Philadelphia, Pa: WB Saunders Co; 1994: 467-516.
17. Labarrere CA, Faulk WP. Antigenic identification of cells in spiral artery trophoblastic invasion: validation of histological studies by triple-antibody immunocytochemistry. Am J Obstet Gynecol. 1994; 171:165-171.
18. Labarrere CA, Pitts D, Halbrook H, Faulk WP. Tissue plasminogen activator, plasminogen activatory inhibitor-1 and fibrin as indexes of clinical course in cardiac allograft recipients: an immunocytochemical study. Circulation. 1994;89:1599-1608.
19. Labarrere CA, Pitts D, Halbrook H, Faulk WP. Tissue plasminogen activator in human cardiac allografts. Transplantation. 1993;55:1056-1060.
20. Mehra MR, Ventura HO, Chamber R, et al. Predictive model to assess risk for cardiac allograft vasculopathy: an intravascular ultrasound study. J Am Coll Cardiol. 1995;26:1537-1544.
21. Adams DH, Russell ME, Hancock WW, Sayegh MH, Wyner LR, Karnovsky MJ. Chronic rejection in experimental cardiac transplantation: studies in the Lewis-F 344 model. Immunol Rev. 1993;134: 5-19.
22. Karnovsky MJ, Russell ME, Hancock W, Sayegh MH, Adams DH. Chronic rejection in experimental cardiac transplantation in a rat model. Clin Transplant. 1994;8:308-312.
23. Briscoe DM, Yeung, AC, Schoen EL, et al. Predictive value of inducible endothelial cell adhesion molecule expression for acute rejection of human cardiac allografts. Transplantation. 1995;59: 204-211.
24. Pober JS. Cytokine-mediated activation of vascular endothelium: physiology and pathology. Am J Pathol. 1988;133:426-433.
25. Stovin PGI, Sharples LD, Schofield PM, et al. Lack of association between endomyocardial evidence of rejection in the first six months and the later development of transplant-related coronary artery disease. J Heart Lung Transplant. 1993;12: 110-116.
26. Faulk WP, Labarrere CA, Pitts D, Halbrook H. Laboratory-clinical correlates of time-associated lesions in the vascular immunopathology of human cardiac allografts. J Heart Lung Transplant. 1993; 12:S125-134.
27. Russell PS, Chase CM, Winn HJ, Colvin RB. Coronary atherosclerosis in transplanted mouse hearts, I: time course and immunogenetic and immunopathological considerations. Am J Pathol. 1994;144:260-274.
28. Pober JS, Cotran RS. The role of endothelial cells in inflammation. Transplantation. 1990;50:537-544.
29. Rose EA, Pepino P, Barr ML, et al. Relation of HLA antibodies and graft atherosclerosis in human cardiac allograft recipients. J Heart Lung Transplant. 1992;11:S120-123.
30. Dunn MJ, Crisp SJ, Rose ML, Taylor PM, Yacoub MH. Antiendothelial antibodies and coronary artery disease after cardiac transplantation. Lancet. 1992;339:1566-1570.
31. Crisp SJ, Dunn MJ, Rose ML, Barbir M, Yacoub MH. Antiendothelial antibodies after heart transplantation: the accelerating factor in transplant-associated coronary artery disease? J Heart Lung Transplant. 1994;13:81-92.
32. Russell PS, Chase CM, Winn JH, Colvin RB. Coronary atherosclerosis in transplanted mouse hearts, II: importance of humoral immunity. J Immunol. 1994;152:5135-5141.
33. Bevilacqua MP, Pober JS, Majeau GR, Cotran RS, Gimbrone MA Jr. Interleukin-1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J Exp Med. 1984;160:618-623.
34. Bevilacqua MP, Pober JS, Majeau GR, Fiers W, Cotran RS, Gimbrone MA Jr. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin-1. Proc Natl Acad Sci USA. 1986;83: 4533-4537.
35. Faulk WP, Gargiulo P, McIntyre JA, Bang NU. Hemostasis and fibrinolysis in renal transplantation. Semin Thromb Hemost. 1989;15:88-98.
36. Wojta J, Gallicchio M, Zoellner H, et al. Thrombin stimulates expression of tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in cultured human vascular smooth muscle cells. Thromb Haemost. 1993;70:469-474.
37. Verstraete M, Collen D. Thrombolytic agents. In: Fuster V, Verstraete M, eds. Thrombosis in Cardiovascular Disorders. Philadelphia, Pa: WB Saunders Co; 1992:175-189.
38. Russell ME, Utans U, Wallace AF, et al. Identification and upregulation of galactose/N-acetylgalactosamine macrophage lectin in rat cardiac allografts with arteriosclerosis. J Clin Invest. 1994; 94:722-730.
39. Faulk WP, Labarrere CA, Pitts D, Halbrook H. Vascular lesions in biopsy specimens devoid of cellular infiltrates: qualitative and quantitative immunocytochemical studies of human cardiac allografts. J Heart Lung Transplant. 1993;12:219-229.
40. Labarrere CA, Pitts D, Nelson DR, Faulk WP. Coronary artery disease in cardiac allografts: association with depleted arteriolar tissue plasminogen activator. Transplant Proc. 1995;27:1941-1943.
41. Faulk WP, Labarrere CA, Nelson DR, Pitts D. Coronary artery disease in cardiac allografts: association with arterial antithrombin. Transplant Proc. 1995;27:1944-1946.
42. Faulk WP, Labarrere CA. Antithrombin III in normal and transplanted human hearts: indication of vascular disease. Semin Hematol. 1994;31(suppl 1):26-33.
43. Gao S-Z, Hunt SA, Schroeder JS, Alderman E, Hill IR, Stinson EB. Does rapidity of development of transplant coronary artery disease portend a worse diagnosis? J Heart Lung Transplant. 1994; 13:1119-1124.
44. Isobe M, Yagita H, Okumura K, Ihara A. Specific acceptance of cardiac allograft after treatment with antibodies to ICAM-1 and LFA-1. Science. 1992;255:1125-1127.
45. Haug CE, Colvin RB, Delmonico FL, et al. A phase I trial of immunosuppression with anti-ICAM-1 (CD54) mAb in renal allograft recipients. Transplantation. 1993;55:766-772.